| Squamous Cell Carcinoma of Unknown Primary studied in …STUDIED_INderived10 of 14show all (up to 200) |
|---|
| → studied in | NCT06589804Phase 3 · recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · condition mapped CURATED_BROADER · 14 trials mapped (7 active) | — | — | Neck Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00588770Phase 3 · active not recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 14 trials mapped (7 active) | — | — | Neck Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03258554Phase 2/Phase 3 · completed Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin · condition mapped ONTOLOGY_EXACT · 14 trials mapped (7 active) | — | — | Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06995508Phase 2 · recruiting Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · condition mapped ONTOLOGY_EXACT · 14 trials mapped (7 active) | — | — | Neck Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · condition mapped ONTOLOGY_EXACT · 14 trials mapped (7 active) | — | — | Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04862650Phase 2 · active not recruiting Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck · condition mapped ONTOLOGY_EXACT · 14 trials mapped (7 active) | — | — | Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868433Phase 1 · recruiting TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer · condition mapped ONTOLOGY_EXACT · 14 trials mapped (7 active) | — | — | Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06636734Phase 2 · recruiting Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial · condition mapped ONTOLOGY_EXACT · 14 trials mapped (7 active) | — | — | Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02538510Phase 1/Phase 2 · completed Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery · condition mapped ALIAS · 14 trials mapped (7 active) | — | — | Neck Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03422536Phase 2 · completed Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma · condition mapped ALIAS · 14 trials mapped (7 active) | — | — | Squamous Cell Carcinoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |